$ACT Up to date company activities and other impor
Post# of 44981
Posted On: 06/23/2014 12:27:47 PM
$ACT Up to date company activities and other important information about $ACT
$ACT
DD Notes ~ http://www.ddnotesmaker.com/ACT
##### recent news/filings ~ source: finance.yahoo.com
Mon, 23 Jun 2014 15:41:00 GMT ~ Unusual Social Activity Today Around Actavis (ACT)
read full: http://www.thestreet.com/story/12753168/1/unu..._ven=YAHOO
*********************************************************
Mon, 23 Jun 2014 12:30:00 GMT ~ Actavis and Forest Laboratories Announce Appointment of C. David Nicholson, PhD to lead Actavis Global Brands Research and Development
- DUBLIN and NEW YORK, June 23, 2014 /PRNewswire/ -- Actavis plc (ACT) and Forest Laboratories, Inc. (FRX) today announced that C. David Nicholson, PhD will be appointed Senior Vice President, Actavis Global Brands R&D following the close of Actavis' planned acquisition of Forest. In this role, Dr. Nicholson will lead the global teams focused on developing Actavis' significantly expanded branded R&D portfolio, as well as defining long-term product development strategies and collaborations. Dr. Nicholson will join Actavis effective August 4, 2014 and will report to Robert Stewart, who will become the Chief Operating Officer of Actavis following the close. "David is a seasoned R&D leader who has transformed organizations into drug development powerhouses," said Brent Saunders, Chief Executive Officer and President at Forest Laboratories. "He brings an exceptional track record spanning more than 30 years in the industry to this critical brand product development position within the new Actavis. His expertise in the development of a diverse portfolio of products including treatments in women's health, psychiatry, cardiovascular, anesthesiology and immunology, matches exceptionally well with our current portfolio, as well as our therapeutic category focus. He also brings expertise in the development of biological products to our organization. David is the ideal leader for our development-focused branded R&D organization, and we look forward to his contributions in maximizing the value of our existing pipeline, while continuing to expand our development portfolio in key therapeutic areas."
read full: http://finance.yahoo.com/news/actavis-forest-...00003.html
*********************************************************
Mon, 23 Jun 2014 12:30:00 GMT ~ Actavis and Forest Laboratories Announce Appointment of C. David Nicholson, PhD to lead Actavis Global Brands Research and Development
- Actavis plc and Forest Laboratories, Inc. today announced that C. David Nicholson, PhD will be appointed Senior Vice President, Actavis Global Brands R&D following the close of Actavis’ planned acquisition of Forest.
read full: http://finance.yahoo.com/news/actavis-forest-...00690.html
*********************************************************
Fri, 20 Jun 2014 21:11:52 GMT ~ ACTAVIS PLC Files SEC form 8-K, Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation
read full: http://biz.yahoo.com/e/140620/act8-k.html
*********************************************************
Thu, 19 Jun 2014 12:30:00 GMT ~ Actavis Confirms District Court Ruling In Generic Exelon® Patch Patent Suit
- DUBLIN, June 19, 2014 /PRNewswire/ -- Actavis plc (ACT) today confirmed that the United States District Court for the District of Delaware has found certain claims of United States Patent Nos. 6,335,031 and 6,316,023 valid and infringed by Actavis' generic version of Novartis' Exelon® Patch (rivastigmine transdermal system). Actavis is reviewing the court's decision and will evaluate all available options, including an appeal. Exelon® Patch is a prescription medicine used to treat people with mild to moderate dementia associated with Alzheimer's or Parkinson's disease. Actavis' Abbreviated New Drug Application for its generic version of Exelon® Patch is currently pending with the U.S. Food and Drug Administration. Actavis plc (ACT) is a global, integrated specialty pharmaceutical company focused on developing, manufacturing and distributing generic, brand and biosimilar products. Actavis has global headquarters in Dublin, Ireland and U.S. administrative headquarters in Parsippany, New Jersey, USA.
read full: http://finance.yahoo.com/news/actavis-confirm...00533.html
*********************************************************
##### chart ~ source: stockcharts.com
stockcharts.com/c-sc/sc?s=ACT&p=D&b=5&g=0&id=p95448242713
##### chart ~ source: eoddata.com
http://chart.eoddata.com/?e=OTCBB&s=ACT&a...D&b=BB
##### company info ~ source: otcmarkets.com
Link: http://www.otcmarkets.com/stock/ACT/company-info
Ticker: $ACT
OTC Market Place: Not Available
CIK code: not found
Company name: Actavis plc
Incorporated In:
##### extra dd links
Latest filings: http://www.otcmarkets.com/stock/ACT/filings
Latest financials: http://www.otcmarkets.com/stock/ACT/financials
Latest news: http://www.otcmarkets.com/stock/ACT/news - http://finance.yahoo.com/q/h?s=ACT+Headlines
Major holdings: http://data.cnbc.com/quotes/ACT/tab/8.1
Insider transactions (1): http://finance.yahoo.com/q/it?s=ACT+Insider+Transactions
Insider transactions (2): http://www.secform4.com/insider-trading/ACT.htm
Insider transactions (3): http://www.insidercow.com/history/company.jsp?company=ACT
RegSho: http://www.regsho.com/tools/symbol_stats.php?...rch=search
DTCC: http://search2.dtcc.com/?q=Actavis+plc&x=...ISO-8859-1
Spoke company information: http://www.spoke.com/search?utf8=%E2%9C%93&q=Actavis+plc
Corporation WIKI: http://www.corporationwiki.com/search/results...=0&y=0
Short Sales: http://www.otcmarkets.com/stock/ACT/short-sales
Insider Disclosure: http://www.otcmarkets.com/stock/ACT/insider-transactions
Research Reports: http://www.otcmarkets.com/stock/ACT/research
Historical Prices: http://finance.yahoo.com/q/hp?s=ACT+Historical+Prices
Basic Tech. Analysis: http://finance.yahoo.com/q/ta?s=ACT+Basic+Tech.+Analysis
Company Profile: http://finance.yahoo.com/q/pr?s=ACT+Profile
Key Statistics: http://finance.yahoo.com/q/ks?s=ACT+Key+Statistics
Industry: http://finance.yahoo.com/q/in?s=ACT+Industry
Insider Roster: http://finance.yahoo.com/q/ir?s=ACT+Insider+Roster
Income Statement: http://finance.yahoo.com/q/is?s=ACT
Balance Sheet: http://finance.yahoo.com/q/bs?s=ACT
Cash Flow: http://finance.yahoo.com/q/cf?s=ACT+Cash+Flow&annual
Market Watch: http://www.marketwatch.com/investing/stock/ACT
Bloomberg: http://www.bloomberg.com/quote/ACT:US
Morningstar: http://quotes.morningstar.com/stock/s?t=ACT
Bussinessweek: http://investing.businessweek.com/research/st...ticker=ACT
Barchart: http://www.barchart.com/quotes/stocks/ACT
OTC Short Report: http://otcshortreport.com/index.php?index=ACT
Investopedia: http://www.investopedia.com/markets/stocks/ACT/?wa=0
http://www.pennystocktweets.com/stocks/profile/ACT
##### last known share structure ~ source: otcmarkets.com
Market Value: Not Available
Shares Outstanding: Not Available
Float: Not Available
Authorized Shares: Not Available
Par Value: Not Available
##### business description ~ source: otcmarkets.com
DD Notes ~ http://www.ddnotesmaker.com/ACT
$ACT
DD Notes ~ http://www.ddnotesmaker.com/ACT
##### recent news/filings ~ source: finance.yahoo.com
Mon, 23 Jun 2014 15:41:00 GMT ~ Unusual Social Activity Today Around Actavis (ACT)
read full: http://www.thestreet.com/story/12753168/1/unu..._ven=YAHOO
*********************************************************
Mon, 23 Jun 2014 12:30:00 GMT ~ Actavis and Forest Laboratories Announce Appointment of C. David Nicholson, PhD to lead Actavis Global Brands Research and Development
- DUBLIN and NEW YORK, June 23, 2014 /PRNewswire/ -- Actavis plc (ACT) and Forest Laboratories, Inc. (FRX) today announced that C. David Nicholson, PhD will be appointed Senior Vice President, Actavis Global Brands R&D following the close of Actavis' planned acquisition of Forest. In this role, Dr. Nicholson will lead the global teams focused on developing Actavis' significantly expanded branded R&D portfolio, as well as defining long-term product development strategies and collaborations. Dr. Nicholson will join Actavis effective August 4, 2014 and will report to Robert Stewart, who will become the Chief Operating Officer of Actavis following the close. "David is a seasoned R&D leader who has transformed organizations into drug development powerhouses," said Brent Saunders, Chief Executive Officer and President at Forest Laboratories. "He brings an exceptional track record spanning more than 30 years in the industry to this critical brand product development position within the new Actavis. His expertise in the development of a diverse portfolio of products including treatments in women's health, psychiatry, cardiovascular, anesthesiology and immunology, matches exceptionally well with our current portfolio, as well as our therapeutic category focus. He also brings expertise in the development of biological products to our organization. David is the ideal leader for our development-focused branded R&D organization, and we look forward to his contributions in maximizing the value of our existing pipeline, while continuing to expand our development portfolio in key therapeutic areas."
read full: http://finance.yahoo.com/news/actavis-forest-...00003.html
*********************************************************
Mon, 23 Jun 2014 12:30:00 GMT ~ Actavis and Forest Laboratories Announce Appointment of C. David Nicholson, PhD to lead Actavis Global Brands Research and Development
- Actavis plc and Forest Laboratories, Inc. today announced that C. David Nicholson, PhD will be appointed Senior Vice President, Actavis Global Brands R&D following the close of Actavis’ planned acquisition of Forest.
read full: http://finance.yahoo.com/news/actavis-forest-...00690.html
*********************************************************
Fri, 20 Jun 2014 21:11:52 GMT ~ ACTAVIS PLC Files SEC form 8-K, Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation
read full: http://biz.yahoo.com/e/140620/act8-k.html
*********************************************************
Thu, 19 Jun 2014 12:30:00 GMT ~ Actavis Confirms District Court Ruling In Generic Exelon® Patch Patent Suit
- DUBLIN, June 19, 2014 /PRNewswire/ -- Actavis plc (ACT) today confirmed that the United States District Court for the District of Delaware has found certain claims of United States Patent Nos. 6,335,031 and 6,316,023 valid and infringed by Actavis' generic version of Novartis' Exelon® Patch (rivastigmine transdermal system). Actavis is reviewing the court's decision and will evaluate all available options, including an appeal. Exelon® Patch is a prescription medicine used to treat people with mild to moderate dementia associated with Alzheimer's or Parkinson's disease. Actavis' Abbreviated New Drug Application for its generic version of Exelon® Patch is currently pending with the U.S. Food and Drug Administration. Actavis plc (ACT) is a global, integrated specialty pharmaceutical company focused on developing, manufacturing and distributing generic, brand and biosimilar products. Actavis has global headquarters in Dublin, Ireland and U.S. administrative headquarters in Parsippany, New Jersey, USA.
read full: http://finance.yahoo.com/news/actavis-confirm...00533.html
*********************************************************
##### chart ~ source: stockcharts.com
stockcharts.com/c-sc/sc?s=ACT&p=D&b=5&g=0&id=p95448242713
##### chart ~ source: eoddata.com
http://chart.eoddata.com/?e=OTCBB&s=ACT&a...D&b=BB
##### company info ~ source: otcmarkets.com
Link: http://www.otcmarkets.com/stock/ACT/company-info
Ticker: $ACT
OTC Market Place: Not Available
CIK code: not found
Company name: Actavis plc
Incorporated In:
##### extra dd links
Latest filings: http://www.otcmarkets.com/stock/ACT/filings
Latest financials: http://www.otcmarkets.com/stock/ACT/financials
Latest news: http://www.otcmarkets.com/stock/ACT/news - http://finance.yahoo.com/q/h?s=ACT+Headlines
Major holdings: http://data.cnbc.com/quotes/ACT/tab/8.1
Insider transactions (1): http://finance.yahoo.com/q/it?s=ACT+Insider+Transactions
Insider transactions (2): http://www.secform4.com/insider-trading/ACT.htm
Insider transactions (3): http://www.insidercow.com/history/company.jsp?company=ACT
RegSho: http://www.regsho.com/tools/symbol_stats.php?...rch=search
DTCC: http://search2.dtcc.com/?q=Actavis+plc&x=...ISO-8859-1
Spoke company information: http://www.spoke.com/search?utf8=%E2%9C%93&q=Actavis+plc
Corporation WIKI: http://www.corporationwiki.com/search/results...=0&y=0
Short Sales: http://www.otcmarkets.com/stock/ACT/short-sales
Insider Disclosure: http://www.otcmarkets.com/stock/ACT/insider-transactions
Research Reports: http://www.otcmarkets.com/stock/ACT/research
Historical Prices: http://finance.yahoo.com/q/hp?s=ACT+Historical+Prices
Basic Tech. Analysis: http://finance.yahoo.com/q/ta?s=ACT+Basic+Tech.+Analysis
Company Profile: http://finance.yahoo.com/q/pr?s=ACT+Profile
Key Statistics: http://finance.yahoo.com/q/ks?s=ACT+Key+Statistics
Industry: http://finance.yahoo.com/q/in?s=ACT+Industry
Insider Roster: http://finance.yahoo.com/q/ir?s=ACT+Insider+Roster
Income Statement: http://finance.yahoo.com/q/is?s=ACT
Balance Sheet: http://finance.yahoo.com/q/bs?s=ACT
Cash Flow: http://finance.yahoo.com/q/cf?s=ACT+Cash+Flow&annual
Market Watch: http://www.marketwatch.com/investing/stock/ACT
Bloomberg: http://www.bloomberg.com/quote/ACT:US
Morningstar: http://quotes.morningstar.com/stock/s?t=ACT
Bussinessweek: http://investing.businessweek.com/research/st...ticker=ACT
Barchart: http://www.barchart.com/quotes/stocks/ACT
OTC Short Report: http://otcshortreport.com/index.php?index=ACT
Investopedia: http://www.investopedia.com/markets/stocks/ACT/?wa=0
http://www.pennystocktweets.com/stocks/profile/ACT
##### last known share structure ~ source: otcmarkets.com
Market Value: Not Available
Shares Outstanding: Not Available
Float: Not Available
Authorized Shares: Not Available
Par Value: Not Available
##### business description ~ source: otcmarkets.com
DD Notes ~ http://www.ddnotesmaker.com/ACT
(0)
(0)